This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Cardiovascular System, Other  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Insufficient Evidence to Justify Treatment

Colin Baigent, BM BCh, FRCP; Robert Clarke, MD, FRCP

JAMA. 2007;298:1212-1214.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Individuals with homocystinuria, a rare genetic disorder associated with markedly elevated plasma homocysteine levels (ie, 100-300 µmol/L [to convert to mg/dL, divide by 7.397]—at least 10 times higher than the general population), experience rapidly progressive atherosclerosis and associated thromboembolic events in early adulthood. This observation prompted the "homocysteine hypothesis" that moderately elevated homocysteine levels might be of causal relevance to cardiovascular disease in the general population.¹

Many observational epidemiological studies have reported that cases with coronary heart disease (CHD) or stroke have higher homocysteine levels compared with age and sex-matched controls. In 1995, a meta-analysis of observational studies, involving a total of 2297 CHD cases, indicated that a 5 µmol/L higher homocysteine level was associated with about a 70% increase in the risk of CHD.² These studies were mainly retrospective in design, however, and were unable to exclude the possibility that . . . [Full Text of this Article]

Author Affiliations: Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford, England.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Effect of Homocysteine Lowering on Mortality and Vascular Disease in Advanced Chronic Kidney Disease and End-stage Renal Disease: A Randomized Controlled Trial
Rex L. Jamison, Pamela Hartigan, James S. Kaufman, David S. Goldfarb, Stuart R. Warren, Peter D. Guarino, J. Michael Gaziano, and For the Veterans Affairs Site Investigators
JAMA. 2007;298(10):1163-1170.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Perspectives on the soy-breast cancer relation
Messina and Wu
Am. J. Clin. Nutr. 2009;89:1673S-1679S.
ABSTRACT | FULL TEXT  

Homocysteine, vitamins, and vascular disease prevention: more negative results
Soliman and Shalash
Am. J. Clin. Nutr. 2008;87:1069-1070.
FULL TEXT  

Lowering Homocysteine Levels in Patients with Severe Renal Disease
JWatch General 2007;2007:11-11.
FULL TEXT